Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis

References

• Diener H-C, Förderreuther S, Kropp P. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie [Migraine attack therapy and migraine prophylaxis, S1 guideline]. Berlin: Deutsche Gesellschaft für Neurologie [German Society for Neurology]; 2022. Leitlinien für Diagnostik und Therapie in der Neurologie [Guidelines for diagnostics and therapy in neurology]; AWMF register number: 030/057. German. Available from: https://dgn.org/leitlinie/118.
   Google Scholar
• Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world”s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.
   PubMed Web of Science ®Google Scholar
• Amoozegar F, Khan Z, Oviedo-Ovando M, et al. The burden of illness of migraine in Canada: new insights on humanistic and economic cost. Can J Neurol Sci. 2022;49(2):249–262.
   PubMed Web of Science ®Google Scholar
• Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the eurolight project. Eur J Neurol. 2012;19(5):703–711.
   PubMed Web of Science ®Google Scholar
• Seddik AH, Branner JC, Ostwald DA, et al. The socioeconomic burden of migraine: an evaluation of productivity losses due to migraine headaches based on a population study in Germany. Cephalalgia. 2020;40(14):1551–1560.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29.
   PubMed Web of Science ®Google Scholar
• Tu S, Liew D, Ademi Z, et al. The health and productivity burden of migraines in Australia. Headache. 2020;60(10):2291–2303.
   PubMed Web of Science ®Google Scholar
• Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–981.
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe – Evidence from the eurolight study. J Headache Pain. 2018;19(1):10.
   PubMedGoogle Scholar
• Piccinni C, Cevoli S, Ronconi G, et al. A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large italian population along two years. J Headache Pain. 2019;20(1):74.
   PubMed Web of Science ®Google Scholar
• Roessler T, Zschocke J, Roehrig A, et al. Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis. J Headache Pain. 2020;21(1):85.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Atlas of headache disorders and resources in the world 2011. Geneva: World Health Organization; 2011. Available from: https://apps.who.int/iris/bitstream/handle/10665/44571/9789241564212_eng.pdf?sequence=1&isAllowed=y.
   Google Scholar
• Ziegeler C, Brauns G, Jürgens TP, et al. Shortcomings and missed potentials in the management of migraine patients - Experiences from a specialized tertiary care center. J Headache Pain. 2019;20(1):86.
   PubMedGoogle Scholar
• Radtke A, Neuhauser H. Prevalence and burden of headache and migraine in Germany. Headache. 2009;49(1):79–89.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644–655.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470–485.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–488.
   PubMed Web of Science ®Google Scholar
• Allergan Inc. : BOTOX® von Allergan feiert 25 Jahre Zulassung in Deutschland [BOTOX® from Allergan celebrates 25 years of approval in Germany] Internet]2018. updated 2018 Dec 5; cited 2022 Mar 30]. German. Available from: https://www.allergan.de/de-de/news/news/botox-allergan-celebrates-25-years.aspx.
   Google Scholar
• AbbVie Ltd: BOTOX 100 Units: Summary of product characteristics [Internet]. Randalls Way, Leatherhead (UK): Datapharm Ltd; 2022. [updated 2022 May 23; cited 2023 Jan 20]. Available from: https://www.medicines.org.uk/emc/medicine/112.
   Google Scholar
• Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.
   PubMed Web of Science ®Google Scholar
• Diener H-C, Dodick D, Aurora S, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–814.
   PubMed Web of Science ®Google Scholar
• Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394(10210):1765–1774.
   PubMed Web of Science ®Google Scholar
• Gemeinsamer Bundesausschuss [Federal Joint Committee]: Nutzenbewertungsverfahren zum Wirkstoff Erenumab (Migräne-Prophylaxe) [Benefit assessment procedure for the active substance erenumab (migraine prophylaxis)] [Internet]. 2018. updated 2019 May 2; cited 2023 Jan 20]. GermanAvailable from https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/411/.
   Google Scholar
• Gemeinsamer Bundesausschuss [Federal Joint Committee]: Nutzenbewertungsverfahren zum Wirkstoff Galcanezumab (Migräne-Prophylaxe) [Benefit assessment procedure for the active substance galcanezumab (migraine prophylaxis)] [Internet]. 2019. updated 2019 Sept 19; cited 2023 Jan 20]. GermanAvailable from https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/450/.
   Google Scholar
• Gemeinsamer Bundesausschuss [Federal Joint Committee]: Nutzenbewertungsverfahren zum Wirkstoff Fremanezumab (Migräne-Prophylaxe) [Benefit assessment procedure for the active substance fremanezumab (migraine prophylaxis)] [Internet]. 2019. updated 2019 Nov 7; cited 2023 Jan 20]. GermanAvailable from https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/462/.
   Google Scholar
• European Medicines Agency (EMA): EPAR product information - Vyepti, eptinezumab Internet]2022. [updated 2022 Nov 29; cited 2023 Jan 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/vyepti-epar-product-information_en.pdf.
   Google Scholar
• Diener H-C, May A. Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor, Ergänzung der S1-Leitlinie [Prophylaxis of migraine with monoclonal antibodies to CGRP or the CGRP receptor, S1 guideline supplement.]. Berlin: Deutsche Gesellschaft für Neurologie [German Society for Neurology]; 2019. Leitlinien für die Therapie der Migräneattacke und Prophylaxe der Migräne [Guidelines for migraine attack therapy and migraine prophylaxis]; AWMF register number: Supplement to 030/057. German. Available from: https://dgn.org/leitlinie/154.
   Google Scholar
• Statistisches Bundesamt DESTATIS [Federal Office of Statistics]: Bevölkerung nach Nationalität und Geschlecht [Population by nationality and sex] [Internet]2021. [updated 2021 June 21; cited 2023 Jan 20]. German. Available from: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bevoelkerung/Bevoelkerungsstand/Tabellen/zensus-geschlecht-staatsangehoerigkeit-2020.html.
   Google Scholar
• Bundesministerium für Gesundheit : Kennzahlen der Gesetzlichen Krankenversicherung 2010 bis 2022 [Key figures for the statutory health insurance 2010 to 2022] [Internet]2022. [updated 2022 June; cited 2023 Jan 20]. German. Available from: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Statistiken/GKV/Kennzahlen_Daten/KF2022Bund_Juni_2022.pdf.
   Google Scholar
• Andersohn F, Walker J. Characteristics and external validity of the German health risk institute (HRI) database. Pharmacoepidemiol Drug Saf. 2016;25(1):106–109.
   PubMed Web of Science ®Google Scholar
• Ludwig M, Enders D, Basedow F, et al. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57–62.
   PubMed Web of Science ®Google Scholar
• Bundesamt für Soziale Sicherung [Federal Office for Social Security]: Festlegungen nach § 8 Absatz 4 RSAV für das Ausgleichsjahr 2022. [Determinations pursuant to Section 8 (4) RSAV for the compensation year 2022] [Internet]. 2021 [updated 2021 Sep 30; cited 2023 Jan 20]. German. Available from: https://www.bundesamtsozialesicherung.de/fileadmin/redaktion/Risikostrukturausgleich/Festlegungen/2022/03_Klassifikation_AJ2022_Festlegung.zip.
   Google Scholar
• Kassenärztliche Bundesvereinigung (KBV) [National Association of Statutory Health Insurance Physicians ]: Schlüsseltabellen S_BAR2_ARZTNRFACHGRUPPE (OID: 1.2.276.0.76.3.1.1.5.2.23) [Key tables S_BAR2_ARZTNRFACHGRUPPE (OID: 1.2.276.0.76.3.1.1.5.2.23)] [Internet]. 2019 [updated 2019 Apr 1; cited 2023 Jan 20]. German. Available from: https://applications.kbv.de/S_BAR2_ARZTNRFACHGRUPPE_V1.01.xhtml.
   Google Scholar
• Kassenärztliche Bundesvereinigung (KBV) [National Association of Statutory Health Insurance Physicians]: Vereinbarung von Qualitätssicherungsmaßnahmen nach § 135 Abs. 2 SGB V zur schmerztherapeutischen Versorgung chronisch schmerzkranker Patienten [Agreement on quality assurance measures in accordance with Section 135 (2) of the German Social Code, Book V for pain therapy care for patients with chronic pain] [Internet]. 2004. [updated 2016 Oct 1; cited 2023 Jan 20]. German. Available from: https://kbv.de/media/sp/Schmerztherapie.pdf.
   Google Scholar
• Novartis Pharma GmbH. Dossier zur Nutzenbewertung gemäß § 35a SGB V zu Erenumab (Aimovig®) - Modul 3A [Dossier for the benefit assessment according to Section 35a SGB V on erenumab (Aimovig®) - Module 3A]. 2018. German. Available from: https://www.g-ba.de/downloads/92-975-2732/2018-10-22_Modul3A_Erenumab.pdf.
   Google Scholar
• Techniker Krankenkasse (TK). Kopfschmerzreport 2020 – Prävalenz, Pillen und Perspektiven [Headache Report 2020 - Prevalence, Pills and Perspectives]. Hamburg: Techniker Krankenkasse; 2020. Kopfschmerzreport [Headache Report]. German. Available from: https://www.tk.de/resource/blob/2088842/66767380cf7cce49b345b06baa704019/kopfschmerzreport-2020-data.pdf.
   Google Scholar
• Müller B, Dresler T, Gaul C, et al. More attacks and analgesic use in old age: self-reported headache across the lifespan in a German sample. Front Neurol. 2019;10:1000.
   PubMed Web of Science ®Google Scholar
• Hardtstock F, Katsarava Z, Wilke T, et al. Real-world treatment and associated healthcare resource use among migraine patients in Germany. Ann Head Med. 2020;4:4.
   Google Scholar
• Grobe T, Steinmann S, Szecsenyi J. BARMER Arztreport 2017 [BARMER Physician Report 2017]. Berlin: Barmer Ersatzkasse; 2017. Schriftenreihe zur Gesundheitsanalyse [Series of publications on health analysis]; Volume 1. German. Available from: https://www.barmer.de/resource/blob/1026820/40985c83a99926e5c12eecae0a50e0ee/barmer-arztreport-2017-band-1-data.pdf.
   Google Scholar
• Porst M, Wengler A, Leddin J, et al. Migräne und Spannungskopfschmerz in Deutschland: Prävalenz und Erkrankungsschwere im Rahmen der Krankheitslast-Studie BURDEN 2020 [migraine and tension headache in Germany: prevalence and disease severity in the BURDEN 2020 disease burden study]. J Health Monit. 2020;5(S6):1–26. German.
   Google Scholar
• Grobe T, Szecsenyi J. BARMER Arztreport 2021 [BARMER Physician Report 2021]. Berlin: Barmer Ersatzkasse; 2021. Schriftenreihe zur Gesundheitsanalyse [Series of publications on health analysis]; Volume 27. German. Available from: https://www.barmer.de/resource/blob/1027518/043d9a7bf773a8810548d18dec661895/barmer-arztreport-2021-band-27-bifg-data.pdf.
   Google Scholar
• European Medicines Agency (EMA): EPAR product information - Aimovig, erenumab Internet]2018. [updated 2022 Mar 1; cited 2023 Jan 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/aimovig-epar-product-information_en.pdf.
   Google Scholar
• European Medicines Agency (EMA): EPAR product information - Ajovy, fremanezumab Internet]2019. updated 2022 June 7; cited 2023 Jan 20]. Available from https://www.ema.europa.eu/en/documents/product-information/ajovy-epar-product-information_en.pdf.
   Google Scholar
• European Medicines Agency (EMA): EPAR product information - Emgality, galcanezumab Internet]2019. updated 2022 Nov 11; cited 2023 Jan 20]. Available from https://www.ema.europa.eu/en/documents/product-information/emgality-epar-product-information_en.pdf.
   Google Scholar
• Müller B, Dresler T, Gaul C, et al. Use of outpatient medical care by headache patients in Germany: a population-based cross-sectional study. J Headache Pain. 2020;21(1):49.
   PubMed Web of Science ®Google Scholar
• Koch M, Katsarava Z, Baufeld C, et al. Migraine patients in Germany – Need for medical recognition and new preventive treatments: results from the PANORAMA survey. J Headache Pain. 2021;22(1):106.
   PubMed Web of Science ®Google Scholar
• Vo P, Swallow E, Wu E, et al. Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain. J Med Econ. 2021;24(1):900–907.
   PubMed Web of Science ®Google Scholar
• Gemeinsamer Bundesausschuss [Federal Joint Committee]: Beschluss zur Arzneimittel-Richtlinie/Anlage VI: Off-Label-Use, Aktualisierung Teil A Ziffer V, Valproinsäure bei der Migräneprophylaxe im Erwachsenenalter [Decision on the Guideline on Medicinal Products/Annex VI: Off-Label Use, Update Part A Item V, Valproic Acid in the Prophylaxis of Migraine in Adults] [Internet]. 2020. [updated 2020 Aug 1; cited 2023 Jan 20]. German. Available from: https://www.g-ba.de/beschluesse/4212/.
   Google Scholar